Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

Data Privacy

11 posts
NNovartis
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Read More

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

  • 2026-08-22
Novartis Pharma AG Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C…
NNovartis
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Read More

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

  • 2026-08-19
Novartis Pharma AG Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C…
NNovartis
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Read More

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

  • 2026-06-06
Novartis Pharma AG New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica,…
NNovartis
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Read More

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

  • 2026-06-03
Novartis Pharma AG New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica,…
NNovartis
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Read More

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

  • 2026-06-03
Novartis Pharma AG New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1…
NNovartis
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Read More

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

  • 2026-06-03
Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…
NNovartis
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Read More

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

  • 2026-06-01
Novartis Pharma AG New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica,…
NNovartis
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Read More

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

  • 2026-05-27
Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…
NNovartis
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Read More

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

  • 2026-05-26
Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…
NNovartis
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Read More

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

  • 2026-03-23
Novartis Pharma AG New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1…
SSwitzerland
Ailanto, Cubbit launch sovereign S3 storage in Switzerland
Read More

Ailanto, Cubbit launch sovereign S3 storage in Switzerland

  • 2026-02-12
Ailanto has agreed a partnership with Cubbit to offer sovereign, S3-compatible cloud object storage for Swiss enterprises. Hosting…
Switzerland
www.europesays.com